Latest Nelfinavir Stories
The HIV protease inhibitor, Nelfinavir, can be used to treat HER2-positive breast cancer in the same capacity and dosage regimen that it is used to treat HIV.
About 0.2% of pregnant women are HIV positive and 1/3 will pass the virus to their baby before it is born if no treatment is given.
Researchers at the University of California, San Diego and Hunter College of the City University of New York (CUNY) have identified potential human molecular targets of the anti-HIV drug Nelfinavir, which may explain why the drug is also effective as a cancer therapy.
Potential molecular targets of the anti-HIV drug nelfinavir have been identified, and may explain why the drug is also effective as a cancer therapy.
DENVER, April 11, 2011 /PRNewswire/ -- MusclePharm Corporation, a Nevada corporation ("MusclePharm" or the "Company") (OTCBB: MSLP), an expanding U.S.
VIENNA, July 19 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), KaletraÂ® (lopinavir/ritonavir), and Merck's integrase inhibitor, IsentressÂ® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in TruvadaÂ® (tenofovir and emtricitabine) in antiretroviral-naive adult patients.
ABBOTT PARK, Ill., April 28 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) approved once-daily dosing of KaletraÂ® (lopinavir/ritonavir) for adult patients with HIV who have previously taken antiretroviral therapy.
New findings may significantly improve the safety of methadone, a drug widely used to treat cancer pain and addiction to heroin and other opioid drugs, according to researchers at Washington University School of Medicine in St. Louis and the University of Washington in Seattle.
MEXICO CITY, Aug. 7 /PRNewswire-FirstCall/ -- Abbott presented pivotal data at the XVII International AIDS Conference (AIDS 2008) in Mexico City today showing that its investigational Norvir(R) (ritonavir) tablet and the current soft-gelatin capsule provide similar levels of drug in the blood.